Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus LORATADINE REDIDOSE.
BENYLIN vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine